High-flow Nasal Cannula Oxygen Increased Exercise Tolerance

High-flow Nasal Cannula Oxygen Increased Exercise Tolerance

High-flow nasal cannula oxygen therapy (HFNC) increases exercise tolerance — improving endurance times and reducing leg fatigue — in adults with stable idiopathic pulmonary fibrosis (IPF) having exercise-induced low blood oxygen levels, according to a small trial in Japan. Notably, HFNC’s benefits were superior to those of standard oxygen therapy,…

Similar Outcomes for IPF Patients Found for Esbriet, Ofev in Analysis

People with idiopathic pulmonary fibrosis (IPF) had the same mortality and hospitalization rates, and incurred similar healthcare costs, whether they were treated with Esbriet (pirfenidone) or Ofev (nintedanib), a German insurance claims analysis showed. However, the analysis — conducted over five years and involving more than 1,000 patients…

I’m Living With IPF and Need to Slow Down

I’ve always been guilty of putting too much pressure on myself. While I was diagnosed with idiopathic pulmonary fibrosis (IPF) five years ago, I still haven’t learned how to slow down and avoid putting so much pressure on myself. This is despite the disease causing me extreme fatigue, breathlessness,…

ResBiotic Subsidiary Alveolus Bio Focused on Lung, Gut Health

The biotech startup ResBiotic has created a lung disease-focused pharmaceutical spin-off — Alveolus Bio — and launched its first probiotic-based consumer health product called resB Lung Support. The parent company, based in Birmingham, Alabama, and its subsidiary are using $4.5 million in seed funding “to transform the respiratory care landscape…

Vitamin D Helped Reduce Lung Fibrosis in IPF Mice

Vitamin D lessenened lung scarring (fibrosis) in a mouse model of idiopathic pulmonary fibrosis (IPF) by suppressing the activity of the PSAT1 enzyme, and subsequently the mitogen-activated protein kinase (MAPK) pathway, a study shows. PSAT1 is an enzyme that links metabolic and amino acid production pathways. The MAPK pathway is…

Facing IPF, Mortality, and a Future as an Only Child

Growing up as an only child, I’ve spent my whole life hearing what one Washington Post writer calls “a slew of profoundly unflattering and occasionally contradictory stereotypes.” I’ve been told many times how lucky I am that I don’t have to share my parents’ affection with siblings. Or…

Agomab Acquires Origo Biopharma, Will Develop Fibrosis Therapies

Agomab Therapeutics and Origo Biopharma are joining forces to develop new therapies for pulmonary fibrosis (PF) and other conditions caused by excessive tissue scarring, or fibrosis. “Agomab and Origo share a common vision that targeting growth factors has tremendous disease-modifying potential,” Tim Knotnerus, Agomab’s CEO, said in…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums